SCHEMBL22089477

SCHEMBL22089477

Cc1cc(O)cc(Cl)c1CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.50
CHRM1 P11229 1/20 0.50
ALOX15 P16050 1/20 0.50
MAOA P21397 1/20 0.50
TBXA2R P21731 1/20 0.50
ADRA1A P35348 1/20 0.50
HTR2B P41595 1/20 0.50
HSD17B10 Q99714 2/20 0.42
HPGD P15428 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
ESR1 P03372 2/20 0.38
ESR2 Q92731 2/20 0.38
SIRT1 Q96EB6 1/20 0.36
ACHE P22303 2/20 0.36
DBH P09172 1/20 0.35
ALDH1A1 P00352 1/20 0.33
APP P05067 1/20 0.33
MAOB P27338 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29970906 1.00 CYP3A4 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3469757 0.84 CYP3A4 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL5940300 0.84 HSD17B10 (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL27129026 0.80 RAPGEF4 (0.39) CYP3A4CHRM1ALOX15TBXA2RADRA1A
SCHEMBL20561941 0.77 HTR1D (0.35) SIRT1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30937162 0.77 HTR1D (0.35) SIRT1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL22106260 0.75 CYP3A4 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL12401840 0.75 HTR1D (0.47) CYP3A4CHRM1ADRA1AHTR2BALDH1A1
SCHEMBL4681948 0.74 TAAR1 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL16095665 0.74 HSD17B10 (0.42) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 US disclosed
CN-113423684-A Novel thyromimetic agents 速通医疗公司 2021-09-21 CN disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 WO disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 WO disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 US disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 US disclosed
US-20200361849-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2020-11-19 US disclosed
US-20200361849-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2020-11-19 US disclosed
WO-2020118564-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2020-06-18 WO disclosed
WO-2020118564-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2020-06-18 WO disclosed
WO-2020123861-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667606-B2 Thyromimetics TPO, TSHR, TTR CYP3A4 918/4885CHRM1 5/4885ALOX15 1864/4885
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 CYP3A4 1258/4885CHRM1 3/4885ALOX15 1758/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 CYP3A4 1047/4885CHRM1 3/4885ALOX15 1781/4885
US-20200361849-A1 NOVEL THYROMIMETICS TPO, THOP1, TSHR CYP3A4 965/4885CHRM1 4/4885ALOX15 1244/4885
US-20210053917-A1 NOVEL THYROMIMETICS TPO, TSHR, CHRM1 CYP3A4 1132/4885CHRM1 3/4885ALOX15 1913/4885
US-11827596-B2 Thyromimetics TPO, TSHR, TTR CYP3A4 918/4885CHRM1 8/4885ALOX15 1416/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB CYP3A4 2516/4885CHRM1 122/4885ALOX15 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.